AG真人官方

Can-Fite BioPharma (CANF) has filed a Rule 424(b)(4) prospectus for a best-efforts capital raise. The company will sell up to 1.25 million American Depositary Shares (ADSs) at $0.60 each (1 ADS=300 ordinary shares) bundled with 2.5 million two-year Common Warrants exercisable at $0.60. Investors that would exceed 4.99%/9.99% ownership can instead buy up to 7.083 million Pre-Funded Warrants at $0.599, each exercisable for one ADS at $0.001. The filing also registers 583,333 Placement Agent Warrants (exercise price $0.75) and up to 24.33 million ADSs issuable upon warrant exercise.

Gross proceeds could reach $4.99 million; after 7% placement fee, 1% management fee and ~$246k expenses, net proceeds are estimated at $4.19 million. Funds will support R&D, clinical trials and general corporate purposes at management鈥檚 discretion.

Capital impact: outstanding ordinary shares rise from 3.997 billion (13.323 million ADSs) to 4.372 billion (14.573 million ADSs), a ~9% increase, or ~63% if all Pre-Funded Warrants are exercised immediately (total 8.333 million new ADSs). The warrants鈥� two-year term and low exercise price cap potential upside for existing holders and add future dilution.

CANF鈥檚 ADSs closed at $1.02 on 22 Jul 2025, a 70% premium to the $0.60 offer price, suggesting short-term pricing pressure. The deal includes 90-day lock-ups for the company and insiders and a one-year prohibition on variable-rate financings (subject to waiver).

Can-Fite BioPharma (CANF) disclosed a $5.0 million best-efforts public offering of equity and warrants. The July 28, 2025 deal comprises (i) 1.25 million ADSs (each equal to 300 ordinary shares) and (ii) 7.08 million pre-funded warrants plus 16.67 million common warrants, all priced at a combined $0.60 per ADS/ warrant unit ($0.599 for pre-funded units). Net proceeds after fees are expected to be $4.19 million.

The pre-funded warrants are immediately exercisable at $0.001 per ADS with no expiry; common warrants carry a $0.60 strike and two-year tenor. Exercisability is capped at 4.99% (optionally 9.99%) beneficial ownership. A single investor executed a definitive Securities Purchase Agreement that imposes a 90-day standstill and prohibits 鈥渧ariable-rate鈥� financings for one year.

H.C. Wainwright acted as exclusive placement agent, earning 7% cash commission, 1% management fee, fixed expenses (~$165k) and agent warrants covering 7% of ADSs/pre-funded warrants, exercisable at $0.75.

Funds will support additional working capital, R&D and clinical trials. The offering, registered on Form F-1 (File No. 333-288890) declared effective July 28 2025, is expected to close on or about July 29 2025, subject to customary conditions.

flyExclusive, Inc. (NYSE American: FLYX) filed an 8-K (Item 8.01) announcing it has waived the lock-up that restricted EG Sponsor LLC from selling 5.625 MM Class A shares and 4.333 MM warrants until 27 Dec 2026. The waiver, executed 25 Jul 2025 and effective immediately, is intended to clear a March 2025 Russell 2000 rule that bars index inclusion while such restrictions are in place. Management believes Russell inclusion would raise trading volume, liquidity and enhance access to its at-the-market program.

The Audit & Risk Committee and the full Board (with interested directors Gregg Hymowitz and Gary Fegel recused) approved the waiver in line with company policy. All other terms of the 2021 Letter Agreement between the Company and EG Sponsor LLC remain unchanged.

No financial metrics were disclosed; the filing is limited to governance actions surrounding the share release and potential index listing.

On 28 Jul 2025, Can-Fite BioPharma Ltd. (CANF) furnished a Form 6-K to the SEC. The sole substantive disclosure is that a press release titled 鈥淏reakthrough Study from UCLA Demonstrate Can-Fite鈥檚 Piclidenoson as a Treatment for Vascular Dementia鈥� is attached as Exhibit 99.1. The filing does not include financial figures, guidance or trial details, but the headline signals an expansion opportunity for Piclidenoson into the large, underserved vascular dementia market. If future data confirm efficacy, this new indication could materially broaden the drug鈥檚 commercial potential and strengthen CANF鈥檚 pipeline value.

No information is given on study size, statistical significance, regulatory path or timelines. Investors will need the full Exhibit 99.1 or follow-up communications to assess clinical strength, competitive positioning and potential revenue impact.

Can-Fite BioPharma announced the adjournment of its Annual General Meeting of Shareholders originally scheduled for June 23, 2025, due to lack of quorum. The meeting has been rescheduled for June 30, 2025, at 3:00 p.m. Israel time and will be held at the company's offices in Ramat Gan, Israel.

The Form 6-K was signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer of the company. This regulatory filing fulfills the company's obligation to report material events to shareholders under Securities Exchange Act requirements.